ArticleDigestion2026
IL-22 Associates with Venous Thromboembolism in Inflammatory Bowel Disease: A Hypothesis-Generating Study.
Article in Digestion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with inflammatory bowel disease (IBD) are at significantly increased risk for venous thromboembolism (VTE). We hypothesized that (i) the increased risk is associated with elevated levels of typical pro-inflammatory cytokines and (ii) that elevated concentrations of specific cytokines could possibly predict a thromboembolic event.
methodsWe examined 226 well-characterized patients of the Swiss IBD cohort study (SIBDCS); we analyzed serum samples from IBD patients with documented VTE (n = 78) and compared them 2:1 with age- and sex-matched controls without VTE of the same cohort (n = 148). An array of 12 typical proinflammatory cytokines (IL2, IL17a, IL12p70, IL8, IL1b, IL4, IL5, IFN-γ, IL6, IL22, TNF-α, and IL-10) was quantified. Detailed disease characteristics - such as activity (mild, moderate, and quiescent) as well as age at visit, sex, and the time interval between thrombosis and blood collection were statistically analyzed.
resultsIL2, IL17a, IL12p70, IL8, IL1b, IL4, IL5, IFN-γ, IL6, TNF-α, and IL-10 showed no statistical difference between the thrombosis and control group. In contrast, IL-22 levels (0.709 vs. 0.542 pg/mL, p < 0.05) were significantly higher in the VTE group.
conclusionsIL-22, may associate with an increased risk of VTE in IBD in this hypothesis-generating study, whereas the other inflammatory parameters measured were not associated. This marker appears to be independent of disease activity, as the other cytokines, which are considered markers of disease activity, did not show a significant difference in comparison. Further targeted and serial measurements will have to confirm our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.